EU regulatory update · MDCG / European Commission · 3 November 2026
Orphan IVDs Get Their Own Clinical Evidence Guidance: Inside MDCG 2026-6
Why it matters
On 3 November 2026, the European Commission announced a new MDCG document: MDCG 2026-6, "Clinical evidence for orphan in vitro diagnostic medical devices", dated November 2026 [1][2]. Until now, the MDCG's orphan-device guidance, MDCG 2024-10, covered only medical devices under the MDR [3]. MDCG 2026-6 gives IVDs under the IVDR a parallel framework.
The guidance says IVDR clinical evidence requirements should be applied to IVDs for rare diseases or rare circumstances in a "balanced and proportionate" way. It describes when such an IVD can be placed on the market with limitations in clinical performance data [1]. Like all MDCG documents, it is not legally binding [1]. The IVDR requirements on performance evaluation (Article 56 and Annex XIII) are unchanged [1]. MDCG lists the document in its guidance collection [5].
What changed
MDCG 2026-6 is a NEW document. Its main points [1]:
- Orphan criteria. An IVD is an orphan IVD if it is specifically intended to test persons for a disease, condition or circumstance that presents in no more than 12,000 individuals in the EU per year, and if alternatives are insufficient or the IVD offers an expected clinical benefit over alternatives or the state of the art (§4.1). The count is based on incidence, not on the number of tests performed.
- Rare-disease shortcut. A rare disease (no more than 5 in 10,000 persons in the EU) for which the IVD is expected to identify or inform management of no more than 12,000 individuals per year is accepted as sufficient epidemiological justification (§4.2.1).
- Subpopulations and indications. A clinically valid orphan subpopulation, or an orphan indication of an otherwise non-orphan IVD, can qualify. Arbitrarily restricting use to a subpopulation to meet the threshold will not be considered sufficient (§4.2.1, §4.3).
- Acceptable limitations. Limited pre-market clinical performance data can be acceptable when: all available data have been evaluated and limitations identified; the data show the relevant GSPR are met, the benefit-risk ratio is acceptable and a clinical benefit is expected; further pre-market data are not feasible or proportionate; adequate PMPF and PMS plans are in place; and users are informed of the orphan status and the data limitations (§5).
- Non-clinical data and PMPF. Contrived samples, data from similar IVDs or RUO products, in silico models and registry datasets can reduce the pre-market clinical data burden if justified (§6). A structured, detailed PMPF plan, subject to notified body review, is expected (§9).
- Notified bodies and expert panels. Notified bodies should check orphan status early and can issue certificates with conditions, such as defined PMPF within a set period (§10). Expert panel advice through the EMA is optional; panels "will endeavour" to respond within 60 or 90 days (§11).
MDCG 2026-6: does the orphan IVD pathway apply?
Simplified from sections 4, 5, 9 and 10. The guidance is not legally binding; IVDR Article 56 and Annex XIII still apply.
Arbitrary narrowing is not acceptedIf yes, go to 2
- all data evaluated and limitations identified
- GSPR, benefit-risk and expected clinical benefit shown
- more pre-market data not feasible or proportionate
- adequate PMPF/PMS plans
- users told of status and limits
Health institutions (Art. 5(5) in-house IVDs): sections 4–9 and Annexes 3–4 apply as general principles; Part B (notified bodies, expert panels) does not.
Who is affected
Out of scope. Orphan medical devices remain covered by MDCG 2024-10 [3]. Interpretation the two documents use the same 12,000-per-year threshold and a similar two-part structure, so companies with both MDR and IVDR orphan products can align their internal procedures.
The guidance applies to IVDs in all risk classes (§3) [1]. It is aimed at manufacturers, notified bodies, expert panels, health institutions and regulators. Examples given are genetic tests for rare diseases and toxicology tests for uncommon intoxications (§2). For Class D orphan IVDs, the performance evaluation consultation procedure under IVDR Article 48(6) may also apply, and any expert advice obtained should be reflected in the performance evaluation report (§11.3). EU health institutions that make in-house orphan IVDs under Article 5(5) can use the general principles in sections 4 to 9 and Annexes 3 and 4. Part B on notified bodies and expert panels does not apply to them (§3).
Table 1. Expert panel consultation scenarios, from MDCG 2026-6 Table 1 [1]
| Advice | Requested by | When | Remarks |
|---|---|---|---|
| Early stage | Manufacturer | Early in development, before the clinical performance evaluation and/or study (§11.1.1) | Preferred over late-stage manufacturer advice |
| Late stage | Notified body | Early in conformity assessment, e.g. application review (§11.1.2(a)) | Encouraged where the NB disagrees with or is uncertain about the orphan claim |
| Late stage | Manufacturer | Advanced or completed performance evaluation, e.g. legacy IVD (§11.1.2(b)) | Extraordinary measure during IVDR transition periods |
Key dates
Table 2. Key dates
| Date | Milestone | Status |
|---|---|---|
| 25 Jun 2024 | MDCG 2024-10 (orphan medical devices, MDR) published | Verified [3][4] |
| November 2026 | MDCG 2026-6 endorsed and dated | Verified [1] |
| 3 Nov 2026 | European Commission announces MDCG 2026-6 | Verified [2] |
| None stated | MDCG 2026-6 gives no application date or transition period | Verified [1]; Interpretation usable from publication as current MDCG guidance |
What RA teams should do
- Screen your IVD portfolio and pipeline for possible orphan IVDs or orphan indications. Collect EU incidence evidence from sources such as Orphanet, European Reference Network registries and EMA records (§4.1, §4.2.1) [1].
- For each candidate, write an orphan-status justification that is separate from the clinical evidence, and add the orphan-specific factors listed in Annex 2 to the performance evaluation report [1].
- Map the remaining gaps in clinical performance data against the GSPR. Build a PMPF plan with specimen projections and milestones (§7, §9) [1].
- Raise orphan status with your notified body at application stage, and decide whether to request early expert panel advice (§10, §11) [1].
- Update labeling, the IFU and, for Class C and D devices, the SSP so that users are told about the orphan status and data limitations (§5) [1].
- For legacy IVDs in the IVDR transition, check whether late-stage expert panel advice could still feed into the performance evaluation report before notified body review (§11.1.2(b)) [1].
References
- MDCG. MDCG 2026-6: Clinical evidence for orphan in vitro diagnostic medical devices. Medical Device Coordination Group / European Commission, November 2026. https://health.ec.europa.eu/document/download/3c335d66-18db-4ab2-9fdd-fe552e897200_en?filename=mdcg_2026-6_en.pdf (verified 3 November 2026).
- European Commission, DG SANTE. New guidance document MDCG 2026-6 on Guidance on clinical evidence for orphan IVDs. News announcement, 3 November 2026. https://health.ec.europa.eu/latest-updates/new-guidance-document-mdcg-2026-6-guidance-clinical-evidence-orphan-ivds-2026-11-03_en (verified 3 November 2026).
- MDCG. MDCG 2024-10: Clinical evaluation of orphan medical devices. European Commission, June 2024. https://health.ec.europa.eu/document/download/daa1fc59-9d2c-4e82-878e-d6fdf12ecd1a_en?filename=mdcg_2024-10_en.pdf (verified 3 November 2026).
- European Commission, DG SANTE. MDCG 2024-10 - Clinical evaluation of orphan medical devices - June 2024. News announcement, 25 June 2024. https://health.ec.europa.eu/latest-updates/mdcg-2024-10-clinical-evaluation-orphan-medical-devices-june-2024-2024-06-25_en (verified 3 November 2026).
- European Commission. Guidance - MDCG endorsed documents and other guidance. https://health.ec.europa.eu/medical-devices-sector/new-regulations/guidance-mdcg-endorsed-documents-and-other-guidance_en (verified 3 November 2026).
Disclaimer: This post is regulatory intelligence for information only and is not legal or regulatory advice. MDCG guidance is not legally binding; Regulation (EU) 2017/746 sets the requirements. Items marked INTERPRETATION are analysis, not regulatory requirements. Section numbers refer to MDCG 2026-6.